Vivimed Labs soars with JV getting USFDA’s approval for Albendazole Tablets

12 Dec 2018 Evaluate

Vivimed Labs is currently trading at Rs. 38.40, up by 2.50 points or 6.96% from its previous closing of Rs. 35.90 on the BSE.

The scrip opened at Rs. 36.45 and has touched a high and low of Rs. 39.40 and Rs. 36.45 respectively. So far 24850 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 117.80 on 13-Dec-2017 and a 52 week low of Rs. 34.50 on 26-Oct-2018.

Last one week high and low of the scrip stood at Rs. 39.40 and Rs. 35.30 respectively. The current market cap of the company is Rs. 319.78 crore.

The promoters holding in the company stood at 36.58%, while Institutions and Non-Institutions held 5.21% and 58.21% respectively.

Vivimed Labs’ 50:50 Joint Venture (JV) strides vivimed Pte, Singapore has received approval for Albendazole Tablets USP 200mg from the United States Food & Drug Administration (USFDA). This is the second generic approval by USFDA for Albendazole Tablets.

Albendazole Tablets is a generic version of Albenza Tablets of Amneal pharmaceuticals, Inc. According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately $100 million.

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.

Vivimed Labs Share Price

17.63 -0.92 (-4.96%)
31-Dec-2025 15:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1272.00
Cipla 1507.30
Zydus Lifesciences 912.75
Lupin 2104.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×